Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNE2 | O96020 | 1/20 | 0.36 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.36 |
| ▸ | CDK2 | P24941 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 5/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 8/20 | 0.35 |
| ▸ | CCNC | P24863 | 1/20 | 0.35 |
| ▸ | CDK8 | P49336 | 1/20 | 0.35 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.35 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.35 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 7/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.34 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.34 |
| ▸ | KARS1 | Q15046 | 1/20 | 0.34 |
| ▸ | SMPD3 | Q9NY59 | 1/20 | 0.32 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2997648 | 1.00 | CCNE2 (0.36) | CCNE2CCNE1CDK2EGFRADORA3 | |
| SCHEMBL10158820 | 1.00 | CCNE2 (0.36) | CCNE2CCNE1CDK2EGFRADORA3 | |
| SCHEMBL2997650 | 1.00 | CCNE2 (0.36) | CCNE2CCNE1CDK2EGFRADORA3 | |
| SCHEMBL10159014 | 0.97 | EGFR (0.36) | CCNE2CCNE1CDK2EGFRADORA3 | |
| SCHEMBL10159389 | 0.88 | CCNE2 (0.35) | CCNE2CCNE1CDK2ADORA3PRKAG1 | |
| SCHEMBL10158813 | 0.85 | ADORA2A (0.40) | CCNE2CCNE1CDK2EGFRADORA3 | |
| SCHEMBL10158635 | 0.85 | ADORA2A (0.46) | ADORA3ADORA2A | |
| SCHEMBL10158634 | 0.84 | ADORA2A (0.47) | EGFRADORA3ADORA2AADORA1 | |
| SCHEMBL10158805 | 0.84 | ADORA2A (0.46) | CCNE2CCNE1CDK2EGFRADORA3 | |
| SCHEMBL1412227 | 0.84 | ADORA2A (0.46) | CCNE2CCNE1CDK2EGFRADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8193164-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-06-05 | — | — | US | disclosed |
| US-20100190784-A1 | Organic Compounds | NOVARTIS AG | 2010-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190784-A1 | Organic Compounds | CYP1B1, POLR2A, CYP1A1 | CCNE2 437/4885CCNE1 425/4885CDK2 529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.